Free Trial Information
BioCentury | Aug 31, 2018
Clinical News

FDA says Mallinckrodt jaundice candidate not ready for primetime

...Mallinckrodt obtained the therapy's rights via its acquisition of InfaCare Pharmaceutical Corp. for $80 million up front. InfaCare...
Read More
BioCentury | Aug 22, 2018
Company News

FDA rebuffs Mallinckrodt's jaundice compound

...Mallinckrodt obtained the therapy's rights via its acquisition of InfaCare Pharmaceutical Corp. for $80 million up front. InfaCare...
Read More
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

...Leaman as CFO and head of corporate strategy. He was head of corporate development at InfaCare Pharmaceutical Corp....
Read More
BioCentury | Apr 4, 2016
Clinical News

Stannsoporfin: Completed Phase IIb enrollment

...IIb Jasmine trial comparing 3 and 4.5 mg/kg intramuscular stannsoporfin with phototherapy vs. phototherapy alone. InfaCare Pharmaceutical Corp....
Read More
BioCentury | Oct 28, 2008
Financial News

InfaCare raises $28 million

...also a new investor, joined existing investors FirstMark Capital and Atlas Venture in the round. InfaCare's...
...formation is expected to start Phase III testing next year. HealthCare Venture's Harold Werner joined InfaCare's...
Read More
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
Read More
BioCentury | Oct 23, 2006
Company News

InfaCare management update

InfaCare Pharmaceutical Corp. , Plymouth Meeting, Penn. Business: Hematology Hired: Ronald Dundore as VP of regulatory and quality affairs, formerly director of U.S. regulatory affairs at AstraZeneca plc WIR Staff Hematology...
Read More
BioCentury | Aug 21, 2006
Finance

'A' after 'angel'

...6/12/06 $55.0 Nabriva 1/31/06 $50.8 Asuragen 6/1/06 $49.0 Lux (A) 7/19/06 $49.0 Intranasal 8/15/06 $39.1 InfaCare...
Read More
BioCentury | Jul 3, 2006
Company News

InfaCare management update

InfaCare Pharmaceutical Corp. , Plymouth Meeting, Penn. Business: Hematology Hired: Simon Tulloch as CMO, formerly SVP and head of U.S. R&D at Shire Pharmaceuticals Group plc WIR Staff...
Read More
BioCentury | Mar 11, 2006
Financial News

InfaCare raises $30 million

...Atlas' Peter Barrett and Pequot's Patrick Enright will join InfaCare's board. Leerink was placement agent. InfaCare's...
Read More
Items per page:
1 - 10 of 15
BioCentury | Aug 31, 2018
Clinical News

FDA says Mallinckrodt jaundice candidate not ready for primetime

...Mallinckrodt obtained the therapy's rights via its acquisition of InfaCare Pharmaceutical Corp. for $80 million up front. InfaCare...
Read More
BioCentury | Aug 22, 2018
Company News

FDA rebuffs Mallinckrodt's jaundice compound

...Mallinckrodt obtained the therapy's rights via its acquisition of InfaCare Pharmaceutical Corp. for $80 million up front. InfaCare...
Read More
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

...Leaman as CFO and head of corporate strategy. He was head of corporate development at InfaCare Pharmaceutical Corp....
Read More
BioCentury | Apr 4, 2016
Clinical News

Stannsoporfin: Completed Phase IIb enrollment

...IIb Jasmine trial comparing 3 and 4.5 mg/kg intramuscular stannsoporfin with phototherapy vs. phototherapy alone. InfaCare Pharmaceutical Corp....
Read More
BioCentury | Oct 28, 2008
Financial News

InfaCare raises $28 million

...also a new investor, joined existing investors FirstMark Capital and Atlas Venture in the round. InfaCare's...
...formation is expected to start Phase III testing next year. HealthCare Venture's Harold Werner joined InfaCare's...
Read More
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
Read More
BioCentury | Oct 23, 2006
Company News

InfaCare management update

InfaCare Pharmaceutical Corp. , Plymouth Meeting, Penn. Business: Hematology Hired: Ronald Dundore as VP of regulatory and quality affairs, formerly director of U.S. regulatory affairs at AstraZeneca plc WIR Staff Hematology...
Read More
BioCentury | Aug 21, 2006
Finance

'A' after 'angel'

...6/12/06 $55.0 Nabriva 1/31/06 $50.8 Asuragen 6/1/06 $49.0 Lux (A) 7/19/06 $49.0 Intranasal 8/15/06 $39.1 InfaCare...
Read More
BioCentury | Jul 3, 2006
Company News

InfaCare management update

InfaCare Pharmaceutical Corp. , Plymouth Meeting, Penn. Business: Hematology Hired: Simon Tulloch as CMO, formerly SVP and head of U.S. R&D at Shire Pharmaceuticals Group plc WIR Staff...
Read More
BioCentury | Mar 11, 2006
Financial News

InfaCare raises $30 million

...Atlas' Peter Barrett and Pequot's Patrick Enright will join InfaCare's board. Leerink was placement agent. InfaCare's...
Read More
Items per page:
1 - 10 of 15